278650 — HLB BioStep Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for HLB BioStep Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	64,403	86,277	52,814	58,169	74,050
Cost of Revenue
Gross Profit	42,056	53,400	36,410	41,046	55,366
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	50,424	81,212	54,075	70,975	91,882
Operating Profit	13,979	5,065	-1,261	-12,806	-17,832
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	12,827	-2,345	326	-11,528	-17,527
Provision for Income Taxes
Net Income After Taxes	11,532	-883	-54.2	-9,693	-20,255
Minority Interest
Net Income Before Extraordinary Items
Net Income	11,031	-1,008	-164	-8,564	-18,962
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	11,031	-1,008	-164	-8,564	-18,962
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	107	-1.65	-2.19	-100	-154
Dividends per Share